GxPinnacle Logo
Skip to content

What Do Inspectors Check for Vendor Requalification and Lifecycle Management in Pharmacovigilance?

Pharmacovigilance systems must periodically requalify vendors and manage their lifecycle. Regulators expect ongoing assessment, performance review, requalification decisions, and documentation of continued suitability.

For: Founders, CEOs & MDs·PV Leads·QA/Compliance·Scientists tasked with documentation

Alignment: Global pharmacovigilance principles (ICH-aligned) and inspection practices

Most useful when: Preparing for inspection, setting up a process, or closing a documentation gap

Key points

  • Pharmacovigilance vendors must be periodically requalified to confirm continued suitability.
  • Requalification must include review of performance metrics, audit outcomes, and CAPA effectiveness.
  • The frequency of requalification must be risk-based and aligned with vendor criticality.
  • Changes in vendor processes, systems, or performance must trigger reassessment.
  • Requalification decisions must determine whether the vendor remains acceptable, requires increased oversight, or should be replaced.
  • Inspection-ready evidence must demonstrate that vendor suitability is actively maintained over time.

What inspectors expect

Each point below should be supported by controlled documents and traceable records.

  • Vendors must be periodically reassessed for continued suitability.
  • Requalification must consider performance, audits, and CAPA.
  • Risk classification must be updated where necessary.
  • Vendors must not continue operating without ongoing evaluation.
  • The MAH must demonstrate continuous control of outsourced activities.

Summary

Inspectors assess whether pharmacovigilance vendors are periodically re-evaluated and managed throughout their lifecycle. They typically review requalification activities, performance trends, audit findings, CAPA effectiveness, and evidence that vendors remain suitable over time.

Common questions

These are the questions this page is designed to answer directly.

  • What is vendor requalification in pharmacovigilance?
  • How often should PV vendors be requalified?
  • What do inspectors check for vendor lifecycle management?
  • How do you reassess vendor suitability in pharmacovigilance?
  • What triggers vendor requalification?
  • How do regulators assess vendor lifecycle management?
  • What is vendor requalification process in PV?
  • How do you manage vendor lifecycle in pharmacovigilance?
  • What evidence is required for vendor requalification?
  • How do you decide whether to continue or terminate a PV vendor?

Evidence objects inspectors expect

Vendor Requalification Records

  • Documented requalification assessments
  • Updated risk classification
  • Requalification decision records
  • Approval or continuation sign-off

Performance Review Outputs

  • Trend analysis of KPI performance
  • Review of timeliness and quality metrics
  • Evidence of performance stability or decline
  • Summary of performance over review period

Audit and CAPA Evaluation

  • Audit findings from previous periods
  • CAPA plans and implementation status
  • Verification of CAPA effectiveness
  • Closure evidence for identified issues

Change Management and Reassessment Triggers

  • Changes in vendor processes or systems
  • Significant personnel changes
  • New services or expanded scope
  • Regulatory inspection findings impacting vendor

Approved Vendor List Updates

  • Updated vendor status and risk level
  • Documentation of continued approval
  • Removal or suspension of vendors
  • Revision history of vendor list

Regulatory Basis (Primary Sources)

  • GVP Module I – requirement for continuous oversight of pharmacovigilance systems
  • GVP Module VI – need for ongoing control of safety data processes
  • ICH E2D – maintaining compliant safety systems over time
  • MHRA GPvP guidance – expectations for ongoing vendor oversight
  • FDA pharmacovigilance guidance – continued responsibility for outsourced activities

Typical Inspection Questions (What Inspectors Ask)

  • How do you ensure your vendors remain suitable over time?
  • When was this vendor last requalified?
  • What performance data was used to reassess this vendor?
  • What happens if a vendor no longer meets requirements?
  • Show me evidence of vendor requalification decisions.

Failure patterns

Vendors are not reassessed after initial qualification.

Performance issues are identified but do not trigger requalification.

CAPA effectiveness is not verified.

Vendor risk classification is not updated over time.

Vendors continue operating despite declining performance or unresolved issues.

What good looks like

  • Defined and documented requalification process.
  • Regular review of vendor performance and audit outcomes.
  • Clear decision-making on vendor continuation or escalation.
  • Evidence of CAPA effectiveness before continuing vendor use.
  • Updated vendor records reflecting current status and risk level.

Operationalisation

  • Define a requalification cycle based on vendor risk level.
  • Review KPI performance, audit findings, and CAPA outcomes regularly.
  • Trigger reassessment when significant changes occur.
  • Document requalification decisions and approvals.
  • Update vendor lists and risk classifications accordingly.
  • Escalate or terminate vendor relationships where necessary.

Need regulatory documentation today?

Save time and reduce inspection risk with structured, pre-built process-ready documentation.
Created by industry professionals, adaptable to your organisation.

Related pre-built documentation inside the app

Get AccessLog In

FAQ

What is vendor requalification in pharmacovigilance?

Vendor requalification is the process of reassessing a vendor’s suitability over time based on performance, compliance, audit results, and risk profile.

How often should vendors be requalified?

Requalification frequency is typically risk-based, with high-risk vendors reviewed more frequently, often annually.

What triggers vendor requalification?

Triggers include performance issues, audit findings, CAPA outcomes, changes in vendor processes, or regulatory events.

Do inspectors review vendor requalification?

Yes. Inspectors assess whether vendors are reassessed and whether continued use is justified based on evidence.

What happens if a vendor fails requalification?

The vendor may require increased oversight, remediation, or termination depending on the severity of the issues.

Why is vendor lifecycle management important?

Lifecycle management ensures that vendors remain compliant and capable over time, reducing regulatory risk and maintaining PV system integrity.

How do you decide whether a pharmacovigilance vendor should be requalified, escalated, or removed?

The decision is based on a documented review of vendor performance, audit outcomes, CAPA effectiveness, risk classification, and any significant operational or regulatory changes. Vendors may be continued, placed under increased oversight, remediated, or removed depending on the level of risk and unresolved compliance concerns.

Sources

Primary guidance used to inform this map. This page is a structured interpretation layer; always validate against the original source documents.

European Medicines Agency (EMA)

  • Guideline on good pharmacovigilance practices (GVP) – Module I
    View source
  • Guideline on good pharmacovigilance practices (GVP) – Module VI
    View source

FDA

ICH

MHRA